KRAS and neoplasm: Among the nine patients with non-metastatic CRC bearing tumor-associated KRAS mutations, the diagnostic sensitivity after enrichment assay was significantly higher than that before the enrichment assay (88.9% vs. 11.1%, P < 0.01).